Open access
Open access
Powered by Google Translator Translator

Chest Medicine

Observational Study: Many Patients with Covid-19 in the ICU Develop Thromboembolism Despite Routine Prophylaxis

29 May, 2020 | 03:17h | UTC

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019 – Critical Care Medicine

 


WHO Interim Guidance: Clinical Management of COVID-19

28 May, 2020 | 10:02h | UTC

Clinical management of COVID-19 – World Health Organization

 


Systematic Review: Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19

28 May, 2020 | 09:59h | UTC

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review – Annals of Internal Medicine

 


Remdesivir for Covid-19: A 5-day Course is Similarly Effective as a 10-day Course

28 May, 2020 | 10:00h | UTC

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 – New England Journal of Medicine

 


Face Coverings for the Public: Laying Straw Men to Rest, by Trisha Greenhalgh

28 May, 2020 | 09:57h | UTC

Face coverings for the public: Laying straw men to rest – Journal of Evaluation in Clinical Practice

Related: Face coverings for the lay public: an alternative view – CEBM Oxford AND Cloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach – Annals of Internal Medicine

 

 


Perspective: Reducing Transmission of SARS-CoV-2

28 May, 2020 | 09:55h | UTC

Reducing transmission of SARS-CoV-2 – Science

 


CDC Updated Guidance: When You Can be Around Others After You Had or Likely Had COVID-19

27 May, 2020 | 02:37h | UTC

When You Can be Around Others After You Had or Likely Had COVID-19 – Centers for Disease Control and Prevention

“I think or know I had COVID-19, and I had symptoms.”

You can be with others after:

  • 3 days with no fever AND
  • Symptoms improved AND
  • 10 days since symptoms first appeared”

 


Study: Loss of Smell and Taste in 2013 Patients with Mild to Moderate COVID-19

27 May, 2020 | 02:35h | UTC

Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19 – Annals of Internal Medicine

 


Just the Facts: What Drugs are Safe and Effective for COVID-19?

27 May, 2020 | 02:31h | UTC

Just the Facts: What drugs are safe and effective for COVID-19? – Canadian Journal of Emergency Medicine

Related Guidelines: NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines – National Institutes of Health AND Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection

“Apart from supportive care, there are no current effective therapeutics for COVID-19”

 


Clinical Guidance: Advanced Pulmonary and Cardiac Support of COVID-19 Patients

27 May, 2020 | 02:27h | UTC

Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIOa Living Working Document – Circulation: Heart Failure

 


A Guide to COVID-19: A Global Pandemic Caused by the Novel Coronavirus SARS-CoV-2

27 May, 2020 | 02:22h | UTC

A Guide to COVID-19: A Global Pandemic Caused by the Novel Coronavirus SARS-CoV-2 – The FEBS Journal

 


Meta-analysis: Efficacy and Safety of Convalescent Plasma for Severe COVID-19

27 May, 2020 | 02:21h | UTC

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis – Canadian Medical Association Journal

 


Duration of Prone Position Sessions: A Prospective Cohort Study

27 May, 2020 | 02:20h | UTC

Duration of prone position sessions: a prospective cohort study – Annals of Intensive Care

 


Podcast: Evidence-Based Medicine for the Management of COVID-19 ARDS

26 May, 2020 | 09:57h | UTC

Critical Perspective: Evidence-Based Medicine for the Management of COVID-19 ARDS – American Thoracic Society

Related Perspective from the Author: In Defense of Evidence-Based Medicine for the Treatment of COVID-19 ARDS – Annals of the American Thoracic Society

 


Perspective: “Here’s What Needs to Happen Before We Can All Get Vaccinated for COVID-19”

26 May, 2020 | 09:45h | UTC

Here’s what needs to happen before we can all get vaccinated for COVID-19 – CBC

 


Study: Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients

26 May, 2020 | 09:43h | UTC

Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign” – Journal of the American Academy of Dermatology

 


WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial Due to Safety Concerns

26 May, 2020 | 09:35h | UTC

WHO Pauses Hydroxychloroquine Arm Of COVID-19 Clinical Trial – After Lancet Study Finds Higher Mortality Rate Among Patients Getting The Drug – Health Policy Watch

See also: WHO halts hydroxychloroquine trial for coronavirus amid safety fears – The Guardian AND WHO Halts Hydroxychloroquine Trial Over Safety Concerns – NPR

 


Remdesivir for the Treatment of Covid-19 — Preliminary Report

25 May, 2020 | 02:06h | UTC

Remdesivir for the Treatment of Covid-19 — Preliminary Report – New England Journal of Medicine

Commentaries: Preliminary report on NIAID trial of remdesivir – PulmCrit AND Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery – National Institutes of Health AND Covid-19 study details benefits of treatment with remdesivir, and also its limitations – STAT

 

Related Commentary on Twitter (Thread – Click for more)

 


Hydroxychloroquine and Chloroquine for Covid-19: Large Observational Analysis Finds No Benefit and Possible Harm

25 May, 2020 | 02:03h | UTC

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis – The Lancet

Commentaries: Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? – The Lancet AND What a big new study on malaria drugs as Covid-19 treatments tells us — and what it doesn’t – STAT AND Hydroxychloroquine May Cause More Harm Than Benefit To COVID-19 Patients, Says New Lancet Study – Health Policy Watch

 


Opinion: Why Countries Should Stop Using Anti-malarial Drugs for COVID-19

25 May, 2020 | 02:02h | UTC

Why countries should stop using anti-malarial drugs for COVID-19 – The Conversation

 


Promising Early Results with New Vaccine from China in Phase I Trial

25 May, 2020 | 01:57h | UTC

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

Commentaries: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response – The Lancet AND Early Study Of Covid-19 Vaccine Developed In China Sees Mixed Results – Forbes AND Coronavirus Vaccine Shows Promising Early Results in China – The New York Times AND A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials – Business Insider AND Experts skeptical after researchers report positive vaccine results – CNN AND Two COVID-19 Vaccine Candidates Induce Immune Response In Healthy Volunteers – Health Policy Watch

 


Perspective: The World May Be Overestimating the Power of Vaccines

25 May, 2020 | 01:55h | UTC

The world needs Covid-19 vaccines. It may also be overestimating their power – STAT

 


Editorial – SARS-CoV2 Vaccines: Slow is Fast

25 May, 2020 | 01:54h | UTC

SARS-CoV2 vaccines: Slow is fast – Science

 


Study: 10 of 60 Patients Treated for COVID-19 Persisted with Positive RT-PCR Results from 4 to 24 Days After Hospital Discharge

25 May, 2020 | 01:50h | UTC

Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China – JAMA Network Open

Commentaries: Expert reaction to study on PCR testing results from 60 people after clinical recovery from COVID-19 – Science Media Centre AND 16% of recovered patients test positive for COVID-19 weeks after discharge: study – UPI

 


Meta-Analysis: Corticosteroids May Reduce Mortality for Patients with COVID-19 and ARDS

25 May, 2020 | 01:45h | UTC

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis – Canadian Medical Association Journal

Related: Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 – Clinical Infectious Diseases